RedHill Biopharma (RDHL) Tops Q2 Loss Views
Tweet
Share
E-mailRedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.07), $0.39 better than the analyst estimate of ($0.46).
For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Waste stocks ride AI and healthcare boom as CLH surges 27%
- Berenberg Starts Brooks Macdonald Group PLC (BRK:LN) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
